Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
Covered in this story
What has happened since
- Pfizer is down 1.4% since this was published, 3 days ago.
- Novo Nordisk is down 0.8% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 48 stories mentioning Pfizer, the earliest published 22 May 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.